So, Tevogen Bio Holdings (TVGN) is having a day. The stock is wobbling around on Friday after the company decided to do two very big things at once: explore buying another company and reverse-split its shares by a factor of 50. That's not a typo. Fifty for one.

Let's start with the potential deal. Tevogen announced it has signed a non-exclusive, non-binding letter of intent to evaluate buying Apozeal Pharmaceutical Inc. The goal here is pretty straightforward: to beef up Tevogen's generics business. The company says this "strategic move" is all about developing more cost-effective medicines and making the U.S. pharmaceutical supply chain more affordable and resilient. If it goes through, the acquisition would hand Tevogen some established assets and a pipeline that includes FDA-approved ANDA assets—that's the approval you need for generic drugs.

Ryan Saadi, Tevogen's CEO, framed it as part of the company's mission to support pharmaceutical affordability and domestic manufacturing. He's not putting all his eggs in one basket, though. The company says it's "actively considering other transactions" focused on life sciences businesses. This isn't even the first letter of intent this year; back in February, Tevogen agreed to evaluate a potential deal with Sciometrix Inc., a private healthcare tech company.

Now, about that other thing. While talking up growth via acquisition, Tevogen also approved a reverse stock split of 50-for-1, effective today. A reverse split is often a move companies make when their share price gets very low, consolidating shares to boost the nominal price per share. It doesn't change the company's market value, but it can change the psychology of the stock. In Tevogen's case, the stock had surged as high as $10.80 on Friday before falling back.

And that brings us to the stock's current state, which is... not great. With a market cap of $1.56 billion, institutional ownership is just 2.4%. The technical picture is rough. The stock is trading 34.5% below its 20-day simple moving average and a whopping 58.6% below its 100-day average. Over the past 12 months, shares have cratered by 80.44% and are sitting much closer to their 52-week lows than highs.

The indicators tell a story of a beaten-down stock that might be due for a bounce, but where the downward pressure hasn't let up. The Relative Strength Index (RSI) is at 21.46, which is deep in oversold territory and often a signal that a rebound could be coming. However, the Moving Average Convergence Divergence (MACD) is at -1.4156, with a signal line at -0.9987. Because the MACD is below its signal line, it indicates bearish momentum is still in play. So you have an oversold condition clashing with ongoing selling pressure—a classic mixed signal. Traders might watch key resistance at $15.00 and key support at $7.00.

Market data shows the stock with weak momentum, underperforming the broader market. The verdict from the data? It reveals what some might call a 'High-Flyer' setup that has come back to earth. The weak momentum score points to clear underperformance, but the company's strategic push into generics could be laying groundwork for future moves.

As of publication time on Friday, Tevogen Bio Holdings shares were down 15.41% at $6.56. For those keeping score, that's a new 52-week low.